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We report a case of a 38-year-old-man who presented with altered mental status. The patient was diagnosed with
infective endocarditis (IE) originating from the GORE HELEX septal occluder device, which was placed 15 months
earlier for symptomatic atrial septal defect. Brain imaging revealed shower emboli phenomena from the known IE. The
patient developed hydrocephalus for which external ventriculostomy was performed. Improved neurological status
warranted open heart surgery. The patient was later confirmed to be an intravenous drugs abuser, prejudicing IE. This
case highlights the importance of meticulously monitoring patients with suspected high-risk behavior with an
implanted intracardiac prosthetic device.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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VentriculostomyIntroduction
We report the first case, to the best of ourknowledge in the USA, of GORE HELEX
septal occluder device (GORE-HSO) infective
endocarditis (IE), with shower emboli to the brain
requiring external ventriculostomy drainage,
where the patient’s intravenous drug abuse pre-
disposed to the pathology described.Case report
A 38-year-old man presented in altered mental
status and acute respiratory failure for which he
was emergently intubated. Vitals were significantfor fever of 40.6 C. Physical examination was
remarkable for multifocal pustules on palms, fin-
gers and arms. Laboratory results were significant
for leukocytosis of 18.7  109/L, creatinine 2.5 mg/
dL, troponin 0.74 ng/mL, and procalcitonin
60.76 ng/dL. Urine drug screen was positive for
benzodiazepines and cannabinoids. The patient’s
family confirmed him being an intravenous drug
abuser. Computed tomography of the brain
revealed multiple infarcts. Blood cultures were
drawn and empiric antibiotic therapy was com-
menced. Fifteen months previously, the diagnosis
of symptomatic single defect atrial septal defect
(ASD) was made when the patient presented with
worsening exertional dyspnea, transient ischemia
attacks, and cryptogenic stroke. This ASD
was determined as the cause of his symptomse CCBY-
Figure 1. Transesophageal echocardiogram at the mid esophageal level (A at 33, B at 95) showing large, multilobulated and mobile
echodensities (arrowheads) on either side of the GORE-HELEX septal occluder device (arrow) consistent with vegetations. LA = left atrium;
LV = left ventricle; RA = right atrium.
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which covered the entire defect.
Transesophageal echocardiography revealed a
large, multilobulated mass and a small mobile
mass on either side of the GORE-HSO, consistent
with vegetation (Fig. 1). Magnetic resonance imag-
ing of the brain demonstrated widespread small
nonenhancing punctate acute ischemic infarcts
and punctate parenchymal hyperintensities con-
sistent with shower emboli from the IE. The
patient’s two blood cultures were positive for
methicillin-resistant Staphylococcus aureus.
Asymmetric right pupillary dilation (7 mm vs.
5 mm) 2 days after admission warranted repeated
computed tomography of the brain. It revealed
new left temporal, occipital horn dilatation, and
increased dilatation of the third and both lateral
ventricles, indicating early hydrocephalus. Neuro-
surgery was consulted and external ventricu-
lostomy drainage performed to relieve the
intracranial pressure.
The patient’s neurological and hemodynamic
status improved over the next 3 weeks and he
underwent open heart surgery. Intraoperatively,
extensive scarring of the GORE-HSO with vegeta-
tions encompassing the device on both atrial sides
and the entire atrial septum were appreciated.
The GORE-HSO was removed through a right
atrial approach and the infected interatrial septum
was excised. The resultant large ASD was closed
using the patient’s autologous pericardium. The
resected specimen cultures remained negative.
He was treated for 6 weeks with vancomycin, cef-
taroline, daptomycin, and rifampin. His postoper-
ative course was unexceptional and he recoveredwell. The patient is asymptomatic with biannual
follow-ups in the cardiology clinic.Discussion
Secundum type ASD is a common congenital
heart defect and newer imaging modalities have
fashioned their percutaneous closure popular. The
three commonly used devices are the Amplatzer
(St. Jude Amplatzer, AGA Medical Corporation,
Plymouth, MN, USA), the CardioSEAL-STARflex
(NMT’s CardioSEAL-STARflex, W.L. Gore &
Associates, Inc., Flagstaff, AZ, USA), and the
GORE-HSO (Helex Septal Occluder, W.L. Gore
& Associates, Inc., Flagstaff, AZ, USA), with
CardioSEAL withdrawn in October 2006 and
ceased operations in 2011.
The first description of the GORE-HSO implan-
tation was in 2001 [1] and it was approved by the
United States Food and Drug Administration in
2006. A clinical trial of the GORE-HSO proved
successful implantation in 96% of the patients
with no reported IE [2]. The study cohort pooled
clinical results on the feasibility, pivotal, contin-
ued access, and postapproval studies on the
GORE-HSO. It demonstrated a composite clinical
success of 93%, with no stated IE in this largest
study of 435 patients [3]. A nonrandomized, multi-
center trial of 119 patients who underwent HSO
placement showed clinical success of 91.7% versus
83.7% who underwent surgery, with no described
IE [4].
A case of GORE-HSO culture-negative IE has
been reported in The Netherlands [5]. We report
the first case, to the best of our knowledge, in
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with shower emboli to the brain causing hydro-
cephalus, requiring external ventriculostomy drai-
nage and removal of the infected device.
Generally, 12 months of postprocedural antibi-
otic prophylaxis are recommended. Nonetheless,
intravenous drug abuse renders any antibiotic
prophylaxis inadequate and prejudices to pro-
gression of IE. The all-embracing infection could
be explained from contiguous spread from the
device, through the septum and to the left side
of the septum as evidenced with the infected
interatrial septum. Neither the patient nor his
family reported intravenous drug usage before
the GORE-HSO placement; moreover, the patient
did not take any postprocedural antibiotics. Prac-
titioners’ vigilance in drug screening patients
prior to intracardiac prosthetic device implanta-
tion can prevent such high morbidity and mortal-
ity complications.References
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